Collaboration, License And Option Agreement Sample Contracts

First Amendment to Collaboration, License and Option Agreement (November 3rd, 2016)

THIS FIRST AMENDMENT TO COLLABORATION, LICENSE AND OPTION AGREEMENT (the "Amendment") is entered into as of September 7, 2016 (the "Amendment Date"), by and between AURIGENE DISCOVERY TECHNOLOGIES LIMITED, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India ("Aurigene"), and CURIS, INC., a corporation organized under the laws of Delaware, USA, having an address of 4 Maguire Road, Lexington, Massachusetts 02421-3112, USA ("Curis").

COLLABORATION, LICENSE AND OPTION AGREEMENT by and Between ACCELERON PHARMA, INC. And CELGENE CORPORATION (August 4th, 2016)

This Collaboration, License and Option Agreement (this "Agreement") dated the 20th day of February, 2008 (the "Execution Date") is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 149 Sidney Street, Cambridge, MA 02139 ("Acceleron"), and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 ("Celgene"). Acceleron and Celgene may each be referred to herein individually as a "Party" and collectively as the "Parties."

Collaboration, License and Option Agreement (February 24th, 2015)

THIS COLLABORATION, LICENSE AND OPTION AGREEMENT (the Agreement) is entered into as of January 18, 2015 (the Effective Date), by and between AURIGENE DISCOVERY TECHNOLOGIES LIMITED, a company organized under the laws of India, having an address of 39-40, KIADB Industrial Area, Phase II, Electronic City Hosur Road, Bangalore - 560100 Karnataka, India (Aurigene), and CURIS, INC., a corporation organized under the laws of Delaware, USA, having an address of 4 Maguire Road, Lexington, Massachusetts 02421-3112, USA (Curis).

Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno- Oncology and Precision Oncology Targets Agreement Provides Curis With Option to Exclusively License Aurigenes Antagonists for Immuno-Oncology, Including an Antagonist of PD-L1 and Selected Precision Oncology Targets, Including an IRAK4 Kinase Inhibitor Investigational New Drug (IND) Application Filings for Both Initial Collaboration Programs Expected This Year Curis to Issue 17.1M Shares of Its Common Stock as Up-Front Consideration Managem (January 21st, 2015)

LEXINGTON, Mass., and Bangalore, India, January 21, 2015 (GLOBENEWSWIRE) Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, and Aurigene Discovery Technologies Limited, a specialized, discovery stage biotechnology company developing novel therapies to treat cancer and inflammatory diseases, today announced that they have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets. The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program. The partnership draws from each companys respective areas of expertise, with Aurigene having the responsibility for conducting all discovery and preclinical activities, including IND-enabling studies and providing Phase 1 clinical trial supply,

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF a CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION, LICENSE AND OPTION AGREEMENT by and Between ACCELERON PHARMA, INC. And CELGENE CORPORATION as Amended on August 2, 2011 (September 6th, 2013)

This Collaboration, License and Option Agreement (this Agreement) dated the 20th day of February, 2008 (the Execution Date) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 149 Sidney Street, Cambridge, MA 02139 (Acceleron), and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (Celgene). Acceleron and Celgene may each be referred to herein individually as a Party and collectively as the Parties.

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF a CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION, LICENSE AND OPTION AGREEMENT by and Between ACCELERON PHARMA, INC. And CELGENE CORPORATION August 2, 2011 (September 6th, 2013)

This Collaboration, License and Option Agreement (this Agreement) dated the 2nd day of August, 2011 (the Effective Date) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 128 Sidney Street, Cambridge, MA 02139 (Acceleron), and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (Celgene). Acceleron and Celgene may each be referred to herein individually as a Party and collectively as the Parties.

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF a CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION, LICENSE AND OPTION AGREEMENT by and Between ACCELERON PHARMA, INC. And CELGENE CORPORATION as Amended on August 2, 2011 (August 7th, 2013)

This Collaboration, License and Option Agreement (this Agreement) dated the 20th day of February, 2008 (the Execution Date) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 149 Sidney Street, Cambridge, MA 02139 (Acceleron), and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (Celgene). Acceleron and Celgene may each be referred to herein individually as a Party and collectively as the Parties.

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF a CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION, LICENSE AND OPTION AGREEMENT by and Between ACCELERON PHARMA, INC. And CELGENE CORPORATION August 2, 2011 (August 7th, 2013)

This Collaboration, License and Option Agreement (this Agreement) dated the 2nd day of August, 2011 (the Effective Date) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 128 Sidney Street, Cambridge, MA 02139 (Acceleron), and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (Celgene). Acceleron and Celgene may each be referred to herein individually as a Party and collectively as the Parties.

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF a CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION, LICENSE AND OPTION AGREEMENT by and Between ACCELERON PHARMA, INC. And CELGENE CORPORATION August 2, 2011 (July 3rd, 2013)

This Collaboration, License and Option Agreement (this Agreement) dated the 2nd day of August, 2011 (the Effective Date) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 128 Sidney Street, Cambridge, MA 02139 (Acceleron), and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (Celgene). Acceleron and Celgene may each be referred to herein individually as a Party and collectively as the Parties.

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF a CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION, LICENSE AND OPTION AGREEMENT by and Between ACCELERON PHARMA, INC. And CELGENE CORPORATION as Amended on August 2, 2011 (July 3rd, 2013)

This Collaboration, License and Option Agreement (this Agreement) dated the 20th day of February, 2008 (the Execution Date) is by and between Acceleron Pharma, Inc., a Delaware corporation having its principal office at 149 Sidney Street, Cambridge, MA 02139 (Acceleron), and Celgene Corporation, a Delaware corporation having its principal office at 86 Morris Avenue, Summit, NJ 07901 (Celgene). Acceleron and Celgene may each be referred to herein individually as a Party and collectively as the Parties.